JP2024524158A5 - - Google Patents
Info
- Publication number
- JP2024524158A5 JP2024524158A5 JP2023578067A JP2023578067A JP2024524158A5 JP 2024524158 A5 JP2024524158 A5 JP 2024524158A5 JP 2023578067 A JP2023578067 A JP 2023578067A JP 2023578067 A JP2023578067 A JP 2023578067A JP 2024524158 A5 JP2024524158 A5 JP 2024524158A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tascinimod
- methoxy
- hydroxy
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183481.7 | 2021-07-02 | ||
| EP21183481 | 2021-07-02 | ||
| PCT/EP2022/068063 WO2023275248A1 (en) | 2021-07-02 | 2022-06-30 | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524158A JP2024524158A (ja) | 2024-07-05 |
| JP2024524158A5 true JP2024524158A5 (https=) | 2025-05-26 |
Family
ID=76764937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578067A Pending JP2024524158A (ja) | 2021-07-02 | 2022-06-30 | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277693A1 (https=) |
| EP (1) | EP4363404A1 (https=) |
| JP (1) | JP2024524158A (https=) |
| KR (1) | KR20240029029A (https=) |
| CN (1) | CN117500790A (https=) |
| AU (1) | AU2022303084A1 (https=) |
| CA (1) | CA3221689A1 (https=) |
| IL (1) | IL309486A (https=) |
| MX (1) | MX2023014668A (https=) |
| WO (1) | WO2023275248A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
| JP6647287B2 (ja) | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| BR112023000892A2 (pt) | 2020-07-23 | 2023-02-07 | Univ Erasmus Med Ct Rotterdam | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |
-
2022
- 2022-06-30 AU AU2022303084A patent/AU2022303084A1/en active Pending
- 2022-06-30 CN CN202280043401.8A patent/CN117500790A/zh active Pending
- 2022-06-30 JP JP2023578067A patent/JP2024524158A/ja active Pending
- 2022-06-30 US US18/571,472 patent/US20240277693A1/en active Pending
- 2022-06-30 EP EP22741222.8A patent/EP4363404A1/en active Pending
- 2022-06-30 MX MX2023014668A patent/MX2023014668A/es unknown
- 2022-06-30 KR KR1020247002056A patent/KR20240029029A/ko active Pending
- 2022-06-30 CA CA3221689A patent/CA3221689A1/en active Pending
- 2022-06-30 IL IL309486A patent/IL309486A/en unknown
- 2022-06-30 WO PCT/EP2022/068063 patent/WO2023275248A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2024061267A1 (zh) | 一种药物组合物及其制备方法和用途 | |
| JP2021073284A (ja) | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 | |
| JP2025024064A (ja) | 癌治療 | |
| JP6892381B2 (ja) | 多発性骨髄腫を治療するための薬物の組み合わせ | |
| JP2024524158A5 (https=) | ||
| JP2024533423A (ja) | 薬学的組成物およびその使用 | |
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| JP2019515889A (ja) | （１ｓ，４ｓ）−４−（２−（（（３ｓ，４ｒ）−３−フルオロテトラヒドロ−２ｈ−ピラン−４−イル）アミノ）−８−（（２，４，６−トリクロロフェニル）アミノ）−９ｈ−プリン−９−イル）−１−メチルクロロヘキサン−１−カルボキサミドの固体形態及びその使用方法 | |
| TWI739756B (zh) | 一種含有喹啉衍生物或其鹽的醫藥組成物 | |
| JP2026016402A (ja) | 癌治療 | |
| JP2020510027A5 (https=) | ||
| KR20190064573A (ko) | 혈액 암 치료용 PPARγ 작용제 | |
| CN104650034A (zh) | 一种稳定的阿西替尼化合物 | |
| US10695296B2 (en) | Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient | |
| JP2024524158A (ja) | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 | |
| CN116159062A (zh) | 药物组合物及其用途 | |
| JP7583729B2 (ja) | 経口投与されるジオキソランヌクレオチドを抗ｐｄ１又は抗ｐｄｌ１モノクローナル抗体と組み合わせて用いる肝臓がんの治療法 | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP2024520307A5 (https=) | ||
| TWI726978B (zh) | 一種含有喹啉衍生物或其鹽的藥物組成物 | |
| CN113995728A (zh) | 一种药物组合物及制备方法 | |
| EP3572082A1 (en) | Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drug | |
| CN107648237B (zh) | 氨基嘧啶类化合物的药物组合物及其制备方法 | |
| CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
| TW202245786A (zh) | 喹唑啉化合物及藥物組合物的應用 |